Estrogen receptor alpha and Estrogen receptor beta (ERα and ERβ)

Estrogen receptor alpha and beta are closely related members of the nuclear receptor superfamily, encoded respectively by the ESR1 (ERα) and ESR2 (ERβ) genes[1][2][3][5][7]. They act as ligand-activated transcription factors: when the hormone estrogen binds, these receptors dimerize and translocate to the nucleus, binding to estrogen response elements (EREs) in target gene promoters and modulating gene transcription[2][7]. Both ERα and ERβ share similar modular structures with several functional domains involved in hormone binding, DNA binding, dimerization, and transcriptional activation, although they differ in some regions, particularly in their ligand-binding and transactivation domains[1][2][6]. ERα is primarily expressed in mammary gland, uterus, ovary, bone, liver, and adipose tissue; ERβ is more abundant in the prostate, ovary (granulosa cells), bladder, colon, and immune system, with both present in brain and cardiovascular system[3][4][7]. Physiologically, these receptors mediate development and maintenance of reproductive tissues, skeletal integrity, and have important roles in the cardiovascular, immune, and nervous systems[3]. ER modulation is therapeutically important in hormone-dependent cancers (e.g., ER-positive breast cancer: with tamoxifen, fulvestrant), in osteoporosis (raloxifene), and in menopause symptom management, but there are associated risks such as increased incidence of certain cancers and cardiovascular events[3][7]. Multiple drugs (SERMs, SERDs, estrogens) act as agonists or antagonists at ERα/ERβ, with complex tissue- and isoform-selectivity. These receptors also serve as key biomarkers for predicting response to endocrine therapies, especially in breast cancer management, by immunohistochemical assessment of ER protein, and by gene expression analysis (ESR1, ESR2)[3][7].

Other names

Estrogen receptor (ER)ESR1 (for ERα)ESR2 (for ERβ)Nuclear receptor subfamily 3, group A, member 1 (NR3A1, for ERα)Estrogen nuclear receptor

Agonist (activates transcription after ligand binding), Antagonist (blocks receptor activity), Selective estrogen receptor modulation (tissue- or subtype-selective agonist/antagonist effects), Degradation or downregulation of receptor